BioSpace News Archive

Spectral Medical Inc. announced the opening of three new clinical trials sites, the University of Alabama at Birmingham, Rutgers, The State University of New Jersey, and a major medical center in Wisconsin, bringing the total number of active clinical trial sites to eighteen for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Daré Bioscience, Inc. today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN), and announced that Organon will pay Daré $1.0 million in July 2023.

I-Mab today announced the publication of a manuscript entitled “CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation” in the latest issue of The Journal for Immuno-Therapy of Cancer (JITC).

TiumBio Co., Ltd. and Hansoh Pharmaceutical Group Co., Ltd. announced that the China National Medical Products Administration (NMPA) approved Hansoh’s Investigational New Drug (IND) application for clinical study of HS-10518 (also known as TU2670), the management of moderate to severe pain associated with endometriosis.

Poseida Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for P-CD19CD20-ALLO1, the Company’s first allogeneic dual CAR-T cell product candidate, which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche.

CoImmune, Inc. today announced the publication of preclinical data demonstrating that a strategy based on the company’s proprietary Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell platform provides advantages over single-targeting CARs including improved efficacy and high specificity in a model of acute myeloid leukemia (AML).

Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an AI-powered Third-Party Administrator (TPA) transforming self-funded employer health plans, announces a relationship with NuvoAir U.S., Inc. (“NuvoAir”) to offer virtual care for heart and lung conditions, focusing on asthma, chronic obstructive pulmonary disease (“COPD”) and chronic heart failure (“CHF”), to its employer health plan members and their families.

EDIRNA, Inc. (the " Company " or " EDIRNA "), an innovative biotechnology company focused on RNA-Editing therapeutics, announces establishment of executive management team led by experienced biopharma executive, Christopher W. Kennedy , as the Company’s President and Chief Executive Officer.

DiamiR Biosciences today announced that it has entered into an agreement with JADBio to utilize its Automated Machine Learning (AutoML) Platform and Services for development of predictive models based on DiamiR’s microRNA panels and other factors for risk assessment in Alzheimer’s disease and Rett syndrome.

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that MEI Pharma shareholders vote “FOR” the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.